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Abstract  
Aflatoxins (AFT) are poisonous substances which are classified in Group 1 carcinogenic agents to 
humans by International Agency for Research on Cancer (IARC). AFT can occur naturally in food 
commodities (maize, corn, rice) as a result of fungal contamination in hot and humid environments. 
In the food, toxin contamination can remain during manufacturing and long after fungi have stopped 
being biologically active. Aflatoxin B1 (AFB1) is the most dominant and potent agent from all AFT. 
In developing countries, high exposure to AFB1 can cause chronic toxicity and usually increases 
the incidence of Hepatocellular Carcinoma (HCC). However, in these regions hepatitis B is the most 
common risk factor for HCC cases. Many researches were aimed to enlighten the mechanism and 
the role of two etiological agents on risk of HCC, but the obtained data was conflicting with each 
other. It was uncertain that the indicators/biomarkers might be the contribution of the carcinogenic 
status of the patient; and, the biomarker samples from the subject may only reflect the recent 
effects of the toxin exposure after consumption of AFB1 contaminated commodities. The studies 
were facing with the errors of methods which were un-fit to enlighten the possible interaction 
between Hepatitis B and AFB1 on contribution to HCC. It was pivotal to understand the effect of 
each risk factor in order to prevent and improve public health in poor and undeveloped regions. 
Although some of the studies evaluate AFB1 alone as a considerable factor on HCC risk, according 
to this review it was concluded vice versa. This study was aimed to clarify the main etiological agent 
of HCC where AFB1 and HBV are endangering public health. In additionally, the purpose was to 
enlighten the possible synergistic effect between these two factors among HCC pathogenesis. 
Hence forth, appropriate and right applications could be conducted in undeveloped countries in 
order to protect public health.  
 
 
 
 
Introduction 
 
Hepatocellular carcinoma (HCC) is one of the 
direst diseases which cause mortalities more than 
600,000 people each year. Chronic hepatitis B 
infection and aflatoxin (AFB1) exposure play crucial 
role in occurrence of HCC in developing countries. 
4.6–28.2% of all global HCC cases may be 
attributable to AFB1 exposure. Moreover, if the 
individuals are exposed chronic hepatitis B virus 
(HBV) and AFB1 together, cancer risk is becoming 
more solemn through increasing the risk 30 times 
greater [1]. Hepatitis B is the most serious and 
frequent illness in developing countries and mainly is 
responsible for 80% of HCC cases around the world. 
Approximately, more than one million deaths occurred 
due to hepatitis B infection in countries, such as Africa 
and Asia. In these poor and undeveloped regions, 
people are suffering under harsh living conditions 
(such as poverty, scarcity and lack of sufficient health 
facilities and drugs) which promote HBV prevalence 
and AFB1 exposure. These two potent agents are 
endangering the public health since for a long time [2, 
3]. 
Epoxidation of aflatoxin to 8, 9-epoxide by 
CP450 enzyme plays pivotal role in the pathway of the 
hepatocellular carcinoma; bind the guanine bases 
particularly on the third base of codon 249 of the p53 
gene to form aflatoxin-N7-guanine (AFB1-N7-Gua). It 
was observed that aflatoxin can impact on p53 
suppressor gene which is responsible for preventing 
cell cycle progression. Also, it was reported that this 
type of mutations dominate in the regions with high 
aflatoxin contamination [4, 5]. Several studies 
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suggested that, in countries with high incidence of 
HCC, chronic infection with HBV was associated with 
high aflatoxin exposure; and within the regions of 
incident, infection and toxin consumption were two 
major etiological risk factors for HCC and further 
health issues, pending to AFB1 [6]. 
Interaction between AFB1 and HBV causing 
HCC was depicted by several possible mechanisms. 
Initially, HBV could induce the conversion AFB1 to 
AFB1-8, 9-epoxide by specific enzyme CP450s in 
both direct and indirect way. HBV originated chronic 
hepatitis or presence of virus itself might promote 
sensitization of hepatocytes during AFB1 toxicity. The 
metabolite has destructive impacts on DNA, by 
binding proteins acute toxicity occurs and viral DNA 
can integrate into the host genome more easily. Direct 
effect of AFB1 and chronic viral hepatitis both may 
provoke these formations [7]. Common occurrence of 
HBV infection and albumin serum adducts during 
aflatoxicosis was demonstrated in Kenya and Gambia 
[8, 9]. Yet, the prevalence of the codon 249 of p53 
gene mutations was found significantly higher among 
HCC patients in South Western Nigeria. In the study, 
all these mutations were demonstrated among all the 
patients with HCC who had the HBsAg positivity [10]. 
In additionally, in the regions where both heavy AFB1 
exposure and hepatitis B infection were common, 
gene p53 codon 249 mutations were observed 
frequently [10, 11]. 
Synergism between AFB1 and hepatitis B 
was observed through clinical studies on HBV-
transgenic mice. There existed a consistent 
mechanism, disclosing the interaction of HBV infection 
which altered the expression of aflatoxin metabolism 
enzymes and consequent extent to DNA to which 
aflatoxins bind. Comprehension of the interaction 
mechanism, were proportional with the public health 
preventive measures against procurement of the HCC 
incidence. As it was emphasized through the course 
of the paper, HBV grants a lethal risk factor for HCC; 
and, there is an alarming necessity to understand 
mutagenic mechanism of HCC, sourced from the 
perpetrating items, threatening public health. Thus, it 
should be examined whether the 249 (ser) mutations 
occurs only in the case of exposure to both HBV and 
AFB1. Yet, the studies from North America, Europe 
and Japan delineated that chronic HBV infection alone 
was insufficient to commence the 249 mutation of 
codon p53 gene. Endemic areas made the 
confirmation further difficult because it was unable to 
clarify the distinct case of factors which were playing a 
role on mutation of gene due to the high prevalence of 
HBV infection in aflatoxin [12]. Kick et al. (2005) found 
out that HBV was not solely affective to cause 249 
(ser) p53 mutations in plasma DNA which was related 
with HCC [13]. In the work of Soini et al. (1996); it was 
mentioned that, hepatitis B virus may activate proto-
oncogenes or inactivate tumour suppressor genes, 
and shall commence neoplastic transformation. Also 
the virus shows ability to integrate into the host DNA, 
and bind to p53 protein; and be further hypothesised 
to propagate vulnerability to hepatocytes to 
carcinogenic damage by AFB1. In the study, it was 
indicated that Mesoamerica happened to be a hotspot 
for 249(ser) mutations in HCC, associating evidence 
of AFB1 contamination in the dietary scale. It was 
emphasized that AFB1 and hepatitis viruses were the 
etiological agents of HCC in the region. Also the data 
from different studies showed a positive correlation 
between dietary intake of toxin and codon 249 
mutations [4]. 
 
 
The role of dietary AFB1 exposure and 
HBV infection on codon 249 of the p53 
gene mutations and HCC  
 
Molecular epidemiological studies were 
depicted that a G to T mis-sense mutation at the third 
base of codon 249 of the p53 gene, affecting an 
arginine to serine substitution, occurred in high 
frequency (up to 67%) in human liver tumours in the 
regions with high risk of aflatoxin exposure. In contrast 
to findings, another experiments were performed, 
using liver tissue from liver-cancer patients in Taiwan 
and Japan, and were scrutinized for the presence of 
aflatoxin-DNA adducts (ADA) as a marker for aflatoxin 
exposure and an AGG to AGT transversion at codon 
249 of the p53 gene. Ten per cent of samples 
containing ADA, indicating definite exposure of the 
subjects to aflatoxin, were found to harbour the codon 
249 mutation, whereas 18% of the samples with no 
detectable adducts also contained the mutation. Since 
the presence of ADA in the liver tissue samples were 
indications of definite recent expo exposure [11].  
Stern et al. (2001) observed the occurrence of 
HBV infection, modifying the effect of aflatoxin 
exposure on the proportion of tumours with any 
mutation in the p53 gene (i.e., aflatoxin by HBV 
interaction). In the conclusion, it was deduced that the 
presence or absence of HBV infection did not change 
the effect of aflatoxin exposure on the prevalence of 
liver tumours with p53 mutations. Moreover, it was 
underlined that there was no significant effect of HBV 
on the proportion of liver tumours with p53 mutations 
[14]. 
Apart from the case of mutations; dietary 
exposure to aflatoxins and determination of aflatoxin 
biomarkers in urine and serum, courses the 
fundamental method to estimate any existing 
correlation between toxin and HCC risk factor. For 
example, in Kenya - Muranga district the subjects with 
higher toxin intakes were residents in areas with an 
elevated incidence of HCC [15]. In another research, 
the conclusion was dictated the significant correlations 
between calculated ingested daily dose of AFB1 and 
adult male incidence of HCC in different parts of 
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South-eastern Africa [16]. 
In ecological studies; AFB1 exposure was 
monitored through samples of urinary excretion of 
AFB1 metabolites and released DNA adducts. In the 
study of mention, data from the cross-sectional survey 
was not sufficient to demonstrate any relation 
between aflatoxin exposure and primary liver cancer 
(PLC) and also failed to explain the influence of the 
aflatoxin urinary biomarkers in the distributed analysis. 
Strong relation with significance was detected 
between HBsAg positivity and PLC occurrence. In the 
survey; extraordinary PLC risk was observed for 
HBsAg positive carriers. In carrier-positive population, 
additional risk was detected chiefly by nutritional and 
dietary practices, enhancing liver cell proliferation, as 
in diets with significant amounts of protein. In contrast, 
aflatoxin was insignificant threat of PLC risk. It was 
suggested that, even though aflatoxin may act as a 
carcinogenic initiator, toxin's contribution to tumour 
generation acts as in a meagre scale for the initiation 
activity, routinely exposing the liver. In this study it 
was proposed that HBsAg positivity was necessary, 
yet gain insufficient factor, thus unlikely reason for 
PLC [17]. 
In the case-control study from Kenya, authors 
had results through systematic sampling of maize and 
serum from participants. The subjects with 
aflatoxicosis, providing serum samples, were 
demonstrated higher aflatoxin B1–lysine adduct 
concentrations in their serum than the control subjects 
did; and, the aflatoxin B1–lysine adducts 
concentrations were measured from the serum of 
case patients are the highest ever reported. It was 
commented that the serum samples concentrations 
with aflatoxin B1–lysine adduct showed the lethal risk 
of acute aflatoxicosis. The serum samples were 
sufficient to analyse 72 (60%) samples for hepatitis B 
surface antigen. The mean age of participants with 
positive titres was 33 years with the rate of 58% 
female. Eight (44%) of 18 cases had positive titres, 
while only 4 (7%) of 54 controls had positive. It was 
found that having positive hepatitis B surface antigen 
titres generates a risk factor for acute hepatic failure. 
When the data was extracted for the course of the 
argument, restricted to participants with negative 
hepatitis B titres, it was found that the subject with 
aflatoxin B1–lysine adduct concentrations at or above 
the median for this subgroup grants a risk factor for 
developing aflatoxicosis [8]. A case-control study in 
Southern Guangxi, China; distribution of serum AFB1-
lysine adducts in HCC cases and controls was 
demonstrated. No significant difference was found in 
the distribution of genotypes between the cases and 
controls. After examinations, levels of serum AFB1- 
lysine adducts were detected higher in the cases than 
controls; yet no statistically significant difference was 
found. Therefore, significant association with HCC risk 
wasn’t demonstrated [18].  
In another case-control study from Thailand, 
two methodological approaches were used to 
estimate HCC exposure. Hepatitis B virus was 
claimed as the major perpetrator, excluding the effect 
of the intake of toxin contaminated food and AFB1-
albumin adducts in serum [19]. 
In the chort study, roles of HBV and AFB1 in 
the development of liver cancer were evaluated in 
Shanghai, China. Additionally; 1 year-long survey of 
market nutritive products in Shanghai was upheld to 
estimate the aflatoxin exposure in the study 
population, quantitatively. After processing, 
approximately 70,000 subjects per year as a follow-
up, 55 cases of hepatocellular carcinoma (HCC) were 
identified; monoclonal antibody column and HPLCs 
analysis were done on 267 control samples and 55 
HCC patients. AFB1-N7-gua adducts were detected in 
the 18 of the urine samples from case group and 31 of 
the control group. Also, in the control group number of 
AFB1 biomarker in urine was higher than the HCC 
case group [20]. Concurrent study was displayed the 
similarity [21]. In the study of Quien et al. (1994), 
aflatoxin was detected in rice, peanuts, wheat-flour, 
soy-sauce and milk several market products; and, the 
products, containing peanuts and soya-sauce had the 
highest level of aflatoxin contamination. It was 
estimated that, there was no significant association 
between dietary AFB1 level and HCC risk among the 
cohort members; after adjustment for HBsAg 
positivity. Among all cohort subjects, in dietary AFB1 
(over 113 μg/kg) exposed population (n = 24013), only 
16 HCC cases were observed. However, number of 
observed HCC cases were higher (n = 25) among 
population (n = 23547) when the toxin exposure was 
between 71-113 μg/kg. 14 HCC cases were detected 
among the rest of population (n = 21833) when the 
AFB1 exposure was lower than 71 μg/kg. On the 
contrary, the results of HBsAg and presence of urinary 
aflatoxins alone were significantly associated with 7.3 
and 3.4 fold increases in HCC risk [20]. 
In the study from Wang et al. (2009), there 
existed a statistical significance in dose-respond 
relation between AFB1 urinary metabolite and HCC 
risk, however was not able to demonstrate any 
persistent synergistic interaction between HBV 
infection and Aflatoxin, among the cases with HCC 
diagnosis [22]. In another cohort study it was indicated 
that AFB-N7-Gua adducts was the mostly detected 
biomarker in urine to attain HCC risk. It was depicted 
that aflatoxin was significant agent together with 
Hepatitis B infection in HCC risk, although specific 
role of aflatoxin in human liver cancer was not 
clarified. As distinct from previous endeavors, author 
put attention on urinary metabolites and DNA-adducts, 
thus acquired information about only recent exposure 
to aflatoxins. Assessment of serum albumin aflatoxin 
adducts might reflect dietary exposure in longer term 
[23]. 
Groopman et al. (1993), in China, detected 
total aflatoxin metabolites in urine with a monoclonal 
antibody-based radio-immunoassay. Aflatoxin N7-
guanine (AFB-N7-Gua), in urine and aflatoxin dietary 
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exposure, was compared extensively in the study. 
However, pending to methodology- total metabolites 
were not appropriate for dosimeter measurement for 
exposure status; eventually paving way to the 
methodology with HPLC analysis. Linear regression 
analyses for the urinary levels of biomarker were 
compared to dietary intake of aflatoxin. Positive 
correlation was observed between AFB-N7-guanine 
adduct excretion in urine and toxin intake. Another 
experiment from the same researchers in Gambia, 
West Africa, had the results, presenting similarity to 
the experience in China. As described above, strong 
evidence for the utility of AFB-N7-guanine in urine as 
an appropriate molecular dosimetry marker of 
exposure was proved. In the research, authors also 
had opportunity to investigate the role of chronic 
hepatitis B virus infection in the metabolism of 
aflatoxins. The statistical analysis of the association of 
hepatitis virus status and the excretion of the AFB-N7- 
guanine adduct in urine for the utter subjects revealed 
that AFB-N7-guanine was not related to HBV carrier 
status. The same study group additionally studied on 
testing animals (lab-rats) to determine biomarkers for 
the risk of chronic exposure, rendering a conclusion, 
that the amount of AFB-N7-guanine in urine 
represented only 1% of the total aflatoxin metabolites 
in urine [24]. 
 
 
Evidence of the uncertain relation 
between of AFB1 dietary intake and HCC 
risk 
 
In the report by World Health Organization 
several studies were evaluated. The data showed that 
different measures and mechanisms were employed 
on carcinogenesis than those of employed on codon 
249 mutations. It was deduced that; 249 codon 
mutation of p53 gene mutation might occur if only 
aflatoxin exposure and codon 249 mutations were 
introduced in earlier stages of hepatocarcinogenesis 
[11]. For the verification of the claim, the existence of 
mutations was analysed through animal testing. In the 
article, Fuyimoto et al. (1992), AFB1 effects on 
arginine to serine substation in codon 249 of p53 
gene, were observed by analysing nine tumour kinds, 
induced by AFB1 in nonhuman primates. It was 
discovered that, in addition to the regions with AFB1 
exposure, there were 4 different important hot spots 
that could be affected by toxin. The mutation was 
identified in one of the subjects with hepatocellular 
carcinoma at the second position of codon 175. It was 
further suggested that p53 mutations were not vital for 
AFB1 induced carcinogenesis in the subject-animals; 
thus generating two apparent explanations for these 
findings: First, the mutation might not occur in non-
human primates because of their difference in gene 
structure than human, and in the absence of HBV- 
induced chronic hepatitis. Therefore, it was possible 
that both AFB1 exposure and HBV-induced chronic 
active hepatitis were necessary for induction of the 
mutation. Second argument was that the 
environmental factors may be responsible for the 
mutations for HCC in human [25].  
In one of the epidemiological studies in 
1970`s aflatoxin intake was demonstrated as HCC risk 
factor. However, the same study was lacked the data 
on liver cancer where the only available data was 
belonging to the dates between 1945-1950`s. In fact 
data might show reliability if registered in 1970`s [15]. 
Another study similar to the similar epidemiological 
basis, mentioned some disadvantages of 
methodology; in Transkei region, the samples were 
collected during 1976 and 1977. Also the number of 
patients with HCC and the number of food samples, 
taken in this region were not sufficient for analysis, 
assessing the individual districts [16]. Although, the 
study of non- associations Campbell et al. (1990), 
compromise the contradictory findings; design of the 
ecological studies were inconsistent with the results. 
But, in the co-evaluating studies; food sampling 
methods were deemed insufficient for estimating the 
extent and exposure of total AFB1. Due to the 
procedure based on sampling; the particular nutrition 
products in the markets or in domestic environments; 
the case of seasonal variation, capable of affecting 
the levels of contamination, was excluded. In addition, 
no extensive and individual information about 
contamination levels were available; eventually 
yielding to the conclusion that, toxin exposure level 
was uncertain [8, 15-17]. The case–control study, 
Baumgarther et al. (2004), found strong association 
between aflatoxin concentrations in home grown 
maize, serum B1–albumin adducts, hepatitis B 
surface antigen titres, and aflatoxicosis status. 
However, study was restricted to the retrospective 
setting. The primary case; it was possible that case 
patients might mislead the researchers about the 
amount, source, and quality of maize that was 
consumed differently than controls did. Secondly, the 
aflatoxin concentrations were measured in sampled 
maize might had shown difference from those 
consumed by case patients before the aflatoxicosis 
emerged. In the study any noticeable association 
wasn’t found between the number of maize portions, 
consumed and case status, thwarted by the limited 
accuracy of the food questionnaires. In addition, it was 
possible that some case patients might have 
developed jaundice as a result of undiagnosed 
medical conditions, unrelated to aflatoxicosis [8]. In 
the study in Southern Guangxi, different results than 
the previous studies were presented; yet shown 
issues concerning the nature of the case-control 
design and the limited sample size? The authors also 
mentioned that the evaluation and confirmation would 
be valuable in cohort studies with a larger sample size 
[18]. 
Cohort studies were more accurate to provide 
valid approach to evaluate the role of AFB1, in 
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contrast to case- control and epidemiological studies 
with different methods. The methodology in these 
studies had the obvious and resolute format to 
determine a true relationship between an exposure 
and disease outcome [26]. In the study of Quien et al 
(1994); controls were successfully matched to the 
cases, as both were recruited and sampled at the 
same instant and health status. Moreover, it was 
necessary to enrol large numbers of subjects to 
ensure accuracy of the case for an appropriate rate. 
Also only information about non-associative dietary 
exposure and HCC risk among cohort subjects were 
demonstrated. Questionnaire data was used to 
assess dietary intake and market-survey to determine 
toxin levels in food products within the region. The 
researchers assigned a quantitative aflatoxin 
exposure level to each study subject and connected 
the variable to urinary aflatoxin biomarker status and 
to a liver cancer risk, and failed to find dose-respond 
relation with each of the attained parameters. The 
conclusion was contradictory to another case with 
well-operated observation of relation between AFB1-
N7-Gua biomarker and the cancer risk. In the study; 
the rate of urinary biomarker detection from single 
void urine sample was insufficient. Dietary exposure 
levels were determined through interviews; and, the 
data reflects the daily variation in urinary aflatoxin 
levels of a given individual. Also; due to semi 
quantitative interview instrument, misclassification of 
diet assessment was quite possible. In the study of 
Ronald K et al. (1992), it was found out those urinary 
levels of aflatoxin accurately reflected intake levels of 
the past 24 hours. The data showed that aflatoxin 
biomarker rendered more-likely information than the 
determination of aflatoxin-liver cancer relation by 
means of dietary assessment [20, 23]. 
Groopman et al. (1993) also proved that 
AFB1-N7-Gua was the most convenient biomarker for 
detection of aflatoxin exposure. The author stressed 
that the DNA damage by aflatoxin was the first of 
many other potential factors, involved in the 
etiopathogenesis of liver cancer. For the convenience; 
recurrent cytotoxicity, cell proliferation, and nutritional 
status could distinctively influence the disease 
process; therefore, author emphasized that the 
molecular epidemiological investigations, examining 
only AFB1-N7-Gua, might distort the estimation the 
cancer risk for an individual. The data, was acquired 
from the experiment, indicated that the synergy 
between any biomarker and tumour outcome requires 
tedious interpretation. In the experiment, effects of 
HBV among aflatoxin metabolism steps weren’t 
observed. The author underlined that depending on 
their results, hepatitis B virus had uncertain path for 
carcinoma; and, interaction with aflatoxin was 
unknown. Therefore, according to the author; the 
proper determination the role of aflatoxin in 
carcinogenesis was challenging [24]. 
 
Evaluation of the further necessities to 
determinate the certain role of AFB1 and 
HBV on risk of HCC 
 
Many ecological studies were suggested a 
significant role for the AFB1 in HCC [15, 16]. It was 
indicated in the review study that reducing dietary 
AFB1 levels to below detectable limits may reduce the 
prevelance of HCC [27]. Albeit, the etiological role of 
AFB1 exposure on HCC has been investigated for 50 
years, data on the interaction of HBV infection is 
limited. Hepatitis B virus is an important risk factor for 
primary liver cancer and presence of this viral 
infection complicates many of the studies. Interaction 
between short term AFB1 exposure (dose-dependent) 
and HBV on P53 gene in HepaRG cells was 
investigated in the recent study of Lereau et al. 
(2012). It was observed that as a result of AFB1 
treatment HBV proteins (HBsAg, HBeAg and L 
protein) decreased. AFB1 was assessed as a natural 
antiviral agent. However, it was mentioned that 
correlation between the applied doses to the cells in 
the study and AFB1 liver concentrations after human 
dietary exposure was not clear. Also, amount of 
AFB1-N7-guanine between HBV infected and non-
infected cells were not different from each other. It 
was suggested that DNA damage by AFB1 wasn’t 
affected by HBV infection. The authors emphasized 
that for the codon 249 of p53 gene precise evaluation 
of adduct formation levels and DNA repair at base 
position of relevance HCC, is necessary for further 
analyses [28]. 
It was observed in several studies that 
development of biomarkers for measuring AFB1 
metabolites and AFB1-DNA and albumin adducts 
were resulted in more accurate and reliable than 
quantification of dietary AFB1 exposure. The results 
from these studies weren’t totally consistent, and 
especially in cohort studies quantification of lifetime 
individual exposure to aflatoxin was extremely difficult. 
A significant finding of all of these studies was the 
dose-dependent relationship between aflatoxin 
exposure and the excretion of the major DNA adduct, 
AFB-N7-guanine, in urine. As a result rapidly excreted 
AFB-N7-guanine adducts only reflects relatively 
recent exposures to AFB1. Temporal relationship 
between DNA damage and long-term risk from 
exposure in humans remained to be established [29]. 
The authors underlined the necessity of the further 
researches to understand interaction between AFB1 
and HBV in regions where HCC cases were common 
and to observe p53 codon 249 mutations on larger 
populations [7, 10]. 
In developing countries with high rate of 
aflatoxin food contamination, AFB1 research 
programs are lack of adequate resources in terms of 
qualified personnel, capital investment, and analytical 
and technical facilities. In additional, together with all 
these factors funding support is necessary for 
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comprehensive examinations in these regions. 
Considering, the reality; great part of the society is 
suffering from scarcity, thus, consumption of 
contaminated food commodities is inevitable. Hence 
for, vaccination programs against hepatitis B virus 
were recommended as a more realistic and cost-
effective strategy for lowering liver cancer incidence 
than removing aflatoxin from the diet [29, 30]. 
AFB1 exposure and HBV infection grants 
pivotal risks for HCC, through two renowned factors, 
endangering the sanitary status of the public health, in 
developing states;. Hence forth, the clinical studies, 
waged to contemplate the issue, are surmounted to 
bring deeper understanding of the agents, acting on 
pathogenesis of liver cancer, through set of analysis. 
The dire need for both point-of-care and clinical 
approach to annihilate the precursors for HCC exists 
for resource-low settings and regions. Including all the 
studies above, incomplete and unclear observations 
and explanations were done in the regions where 
public health is widely under threat of AFB1 exposure 
and HBV. The significant amount of methodological 
optimizations and brand-new approaches are required 
for the prospective aspects of the research, sustaining 
apt opportunity to depict the potent effect of the AFB1. 
The primary issue is that, the many studies were 
diverted to endemic regions, demonstrating high HBV 
rates; and furthermore, the codon 249 mutation of p53 
gene wasn’t examined to show any relevance with the 
AFB1 exposure. The secondary issue is that, the 
reliability of the HCC clinical data and the prevalence 
of HBV were limited. Third and the last issue concerns 
the determination of AFB1 consumption for each 
individual patient was not convenient, and restrains 
with only certain food types.  
The hurdles, encountered through 
determination process, plus the lack of single-patient 
information, also cripples the ecological studies. One 
must notify that the high relevancy, deduced between 
variables on an aggregating level didn’t dictate that 
the similar status might be applied on an individual-
level. Nominate, in cohort studies, utilizing the 
detection of bio-markers from blood/urine samples 
from patient history – long before the eventual 
diagnosis – grants a proper representation of the 
issue, yet failed to deliver the any-possible interaction 
between hepatitis B and AFB1, in depth. In addition; 
mutagenic and coexistent effects of AFB1 on hepatitis 
B weren’t brought to attention, were dismissed without 
a suggestive cause-&-effect, and were recognized 
only through evidence-estimation basis.  
Solemn reliance on bio-marker levels to 
construct an abstract sense between two agents was 
relatively accurate, yet insufficient. Specially; the 
mutation, was thought to be stemmed from AFB1, 
occurring on the codon 249 of p53 gene, might be the 
effective on the carcinogenic factors, such as HBV. 
The cohort studies were motivated to examine the 
frequency of the toxin level in the target region of the 
body. In conclusion; it’s imperative that as long as the 
cases, suggesting the relation between the mutagenic 
effect of hepatitis B and the AFB1's influence on 
codon 249 mutations, are validated; the scientifically 
accurate estimations and claims should be 
constructed. The methods, enforcing the 
determination of toxin (AFB1) biomarkers, should 
present accuracy and reliability, contrary to 
estimation; since previously mentioned adducts 
quantitate and scrutinize the biologically-effective 
dose of toxins on HCC for the individual patient. 
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